Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-20	US$2.320	-2.52%	6,023
26-10-19	US$2.380	-0.83%	3,367
26-10-16	US$2.400	-0.41%	11,892
26-10-15	US$2.410	-2.43%	25,393
26-10-14	US$2.470	0.00%	18,332

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.380USD

Average target price

12.00USD

Spread / Average Target

+404.20%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Kiora Pharmaceuticals, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kiora Pharmaceuticals, Inc.

Company calendar

Real-time Estimate Cboe BZX 11:03:11 2026-10-20 EDT			5-day change	1st Jan Change
2.360 ^USD	-0.84%		-4.45%	+19.80%

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI

Market Cap	15.14M 13.5M 12.51M 11.37M 21.34M 1.44B 21.69M 150M 58.98M 750M 56.82M 55.63M 2.4B	P/E 2026 *	-1.43x	P/E 2027 *	-1.69x
Enterprise Value	15.14M 13.5M 12.51M 11.37M 21.34M 1.44B 21.69M 150M 58.98M 750M 56.82M 55.63M 2.4B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.09%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	KPRX	Delayed
CBOE	KPRX	Real-time

09-08	Kiora Pharmaceuticals, Inc. Appoints Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, Effective September 1, 2026	CI
08-19	Kiora Pharmaceuticals, Inc. Licenses South Korean Ophthalmic Development And Commercialization Rights For KIO-301 To Chong Kun Dang Pharmaceutical Corporation	CI
08-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI
04-07	Kiora Pharmaceuticals Inc - Enters securities purchase agreement on April 3, 2026 - SEC filing	RE
04-05	Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. announced that it expects to receive $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. Announces Resignation of Eric J. Daniels, M.D., MBA as Chief Development Officer, Effective April 17, 2026	CI
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	CI
25-09-15	Kiora Pharmaceuticals files for mixed shelf offering of up to $100 million- SEC filing	RE

Kiora Pharmaceuticals, Inc. Stock

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Valuation: Kiora Pharmaceuticals, Inc.

Chart: Kiora Pharmaceuticals, Inc.

Latest news: Kiora Pharmaceuticals, Inc.

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

Press Releases: Kiora Pharmaceuticals, Inc.

News in other languages: Kiora Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Kiora Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

24-02-09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
23-11-06	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
23-05-12	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
23-02-09	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT

09-08	Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs	NE
08-19	Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation	NE
08-07	Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update	NE
07-02	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium	NE
06-18	Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model	NE

1 day	-0.42%
1 week	-4.45%
Current month	-7.81%
1 month	-11.94%
3 months	-9.23%
6 months	-6.35%
Current year	+19.80%

1 week	2.32	2.49
1 month	2.32	2.8
Current year	1.77	2.91
1 year	1.76	2.91
3 years	1.76	8.98
5 years	1.76	788.4
10 years	1.76	21,060.02

Manager	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	46	2021-07-25
Melissa Tosca DFI	Director of Finance/CFO	46	2024-06-30
Stefan Sperl COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Praveen Tyle CHM	Chairman	66	2023-09-20
Aron Shapiro BRD	Director/Board Member	48	2021-03-31
Brian Strem BRD	Director/Board Member	46	2021-07-25

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/17/26	Keith Lane	Free	General Counsel	55,000	1.2431%
7/1/26	Melissa Tosca	Tax	Chief Financial Officer	-911	0.0206%
7/1/26	Brian Strem	Tax	Chief Executive Officer	-1,869	0.0422%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIORA PHARMACEUTICALS, INC.	-0.84%	-4.45%	-7.45%	-56.51%	15.14M
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	65.83B
LONZA GROUP AG	+2.05%	+10.20%	+12.88%	+87.50%	51.87B
ARGENX SE	+7.13%	+7.85%	+6.16%	+70.97%	51.2B
IQVIA HOLDINGS INC.	+1.22%	+2.65%	+26.19%	+45.15%	43.76B
BEONE MEDICINES AG	+2.27%	+7.69%	+17.99%	+127.54%	42.09B
REVOLUTION MEDICINES, INC.	+6.86%	+2.33%	+257.04%	+589.45%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+4.98%	+30.53%	+25.63%	22.8B
Average	+2.30%	+3.18%	+45.58%	+102.77%	37.58B
Weighted average by Cap.	+2.61%	+3.71%	+49.79%	+122.28%

	2026 *	2027 *
Net sales	-	-
Net income	-9.48M -8.45M -7.83M -7.12M -13.36M -899M -13.58M -93.91M -36.93M -470M -35.58M -34.83M -1.5B	-16.84M -15.01M -13.91M -12.65M -23.73M -1.6B -24.12M -167M -65.6M -835M -63.19M -61.87M -2.67B
Net Debt	-	-